Altretamine for the treatment of metastatic renal cell carcinoma: A Hoosier Oncology Group trial

Robin T. Zon, John Mcclean, Douglas Helman, Rafat Ansari, Joel Picus, Alan Sandler, Stephen D. Williams, Patrick J. Loehrer

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Thirty patients with advanced renal cell carcinoma were treated on a phase 11 trial with altretamine. Altretamine was administered orally at a dosage of 260 mg/m2 days 1 through 14 with cycles repeated every 28 days. Nausea and vomiting were the most common toxicities. Ten percent (3 of 30) experienced Grade 3 gait abnormalities. None of the thirty evaluable patients achieved a complete or partial response. In summary, altretamine did not show antitumor activity in the treatment of advanced renal cell carcinoma.

Original languageEnglish (US)
Pages (from-to)229-231
Number of pages3
JournalInvestigational New Drugs
Volume19
Issue number3
DOIs
StatePublished - Sep 4 2001

Keywords

  • Altretamine
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Fingerprint Dive into the research topics of 'Altretamine for the treatment of metastatic renal cell carcinoma: A Hoosier Oncology Group trial'. Together they form a unique fingerprint.

  • Cite this